...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>PLoS One >Pain burden, sensory profile and inflammatory cytokines of dogs with naturally-occurring neuropathic pain treated with gabapentin alone or with meloxicam
【24h】

Pain burden, sensory profile and inflammatory cytokines of dogs with naturally-occurring neuropathic pain treated with gabapentin alone or with meloxicam

机译：狗的疼痛负担，感觉概况和狗的炎症性细胞因子，单独或用美洛昔康治疗加巴亨坦治疗

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Canine neuropathic pain (NeuP) has been poorly investigated. This study aimed to evaluate the pain burden, sensory profile and inflammatory cytokines in dogs with naturally-occurring NeuP. Twenty-nine client-owned dogs with NeuP were included in a prospective, partially masked, randomized crossover clinical trial, and treated with gabapentin/placebo/gabapentin-meloxicam or gabapentin-meloxicam/placebo/gabapentin (each treatment block of 7 days; total 21 days). Pain scores, mechanical (MNT) and electrical (ENT) nociceptive thresholds and descending noxious inhibitory controls (DNIC) were assessed at baseline, days 7, 14, and 21. DNIC was evaluated using ΔMNT (after-before conditioning stimulus). Positive or negative ΔMNT corresponded to inhibitory or facilitatory pain profiles, respectively. Pain scores were recorded using the Client Specific Outcome Measures (CSOM), Canine Brief Pain Inventory (CBPI), and short-form Glasgow Composite Measure Pain Scale (CMPS-SF). Data from baseline were compared to those of sixteen healthy controls. ΔMNT, but not MNT and ENT, was significantly larger in controls (2.3 ± 0.9 N) than in NeuP (-0.2 ± 0.7 N). The percentage of dogs with facilitatory sensory profile was similar at baseline and after placebo (61.5–63%), and between controls and after gabapentin (33.3–34.6%). The CBPI scores were significantly different between gabapentin (CBPI pain and CBPI overall impression ) and/or gabapentin-meloxicam (CBPI pain and interference ) when compared with baseline, but not placebo. The CBPI scores were not significantly different between placebo and baseline. The concentration of cytokines was not different between groups or treatments. Dogs with NeuP have deficient inhibitory pain mechanisms. Pain burden was reduced after gabapentin and/or gabapentin-meloxicam when compared with baseline using CBPI and CMPS-SF scores. However, these scores were not superior than placebo, nor placebo was superior to baseline evaluations. A caregiver placebo effect may have biased the results.
机译：犬神经病理疼痛（Neup）已被调查很差。本研究旨在评估天然存在的NEUP中狗的疼痛负担，感官概况和炎症细胞因子。具有Neup的二十九条客户拥有的狗被包含在预期，部分掩盖，随机的交叉临床试验中，并用加巴亨坦/安慰剂/加巴帕顿林 - 美洛昔康或加巴喷丁蛋白 - 美洛昔康/安慰剂/加巴亨顿（每次治疗块7天;总计21天）。在基线，第7,14和21天评估疼痛评分，机械（MNT）和电气（ENT）伤害阈值和下降的有害抑制对照（DNIC）。使用ΔMNT（后调理刺激后）评估DNIC。正面或阴性Δmnt分别对应于抑制或促进疼痛谱。使用客户特定的结果措施（CSOM），犬短暂疼痛库存（CBPI）和短型Glasgow复合措施疼痛量表（CMPS-SF）记录疼痛评分。基线数据与十六个健康对照的数据进行比较。 ΔMNT但不是MNT和ENT在对照中显着较大（2.3±0.9 n），而不是NEUP（-0.2±0.7 n）。具有促进感觉型谱的狗的百分比在基线和安慰剂（61.5-63％）和对照后和加巴彭素（33.3-34.6％）之间相似。与基线相比，加巴邦素（CBPI疼痛和CBPI总体印象）和/或加巴彭蛋白 - 美洛昔康（CBPI疼痛和干扰）之间的CBPI分数显着差异，但不会安慰剂。安慰剂和基线之间的CBPI分数没有显着差异。细胞因子的浓度在组或治疗之间没有差异。狗的狗具有缺乏抑制性疼痛机制。使用CBPI和CMPS-SF分数与基线相比，加巴普丁和/或加巴帕顿脲 - 美洛昔康后疼痛负担降低。然而，这些分数不优于安慰剂，安慰剂优于基线评估。护理人员安慰剂效应可能有偏向结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号